Quantitative MRI Evaluation of Ferritin Overexpression in Non-Small-Cell Lung Cancer.

MRI T2* electron paramagnetic resonance spectroscopy ferritin non-small-cell lung cancer

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
18 Feb 2024
Historique:
received: 17 01 2024
revised: 13 02 2024
accepted: 15 02 2024
medline: 24 2 2024
pubmed: 24 2 2024
entrez: 24 2 2024
Statut: epublish

Résumé

Cancer cells frequently present elevated intracellular iron levels, which are thought to facilitate an enhanced proliferative capacity. Targeting iron metabolism within cancer cells presents an avenue to enhance therapeutic responses, necessitating the use of non-invasive models to modulate iron manipulation to predict responses. Moreover, the ubiquitous nature of iron necessitates the development of unique, non-invasive markers of metabolic disruptions to develop more personalized approaches and enhance the clinical utility of these approaches. Ferritin, an iron storage enzyme that is often upregulated as a response to iron accumulation, plays a central role in iron metabolism and has been frequently associated with unfavorable clinical outcomes in cancer. Herein, we demonstrate the successful utility, validation, and functionality of a doxycycline-inducible ferritin heavy chain (FtH) overexpression model in H1299T non-small-cell lung cancer (NSCLC) cells. Treatment with doxycycline increased the protein expression of FtH with a corresponding decrease in labile iron in vitro and in vivo, as determined by calcein-AM staining and EPR, respectively. Moreover, a subsequent increase in TfR expression was observed. Furthermore, T

Identifiants

pubmed: 38397073
pii: ijms25042398
doi: 10.3390/ijms25042398
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : T32CA078586
Pays : United States
Organisme : NIH HHS
ID : R21CA256301
Pays : United States
Organisme : NIH HHS
ID : R21CA270742
Pays : United States
Organisme : NIH HHS
ID : P01CA244091
Pays : United States
Organisme : NIH HHS
ID : P01CA217797
Pays : United States
Organisme : NIH HHS
ID : R50CA243693
Pays : United States
Organisme : NIH HHS
ID : P30 CA086862
Pays : United States

Auteurs

Mekhla Singhania (M)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Amira Zaher (A)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Casey F Pulliam (CF)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Khaliunaa Bayanbold (K)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Charles C Searby (CC)

Department of Pediatrics, University of Iowa, Iowa City, IA 52242, USA.

Joshua D Schoenfeld (JD)

Human Oncology & Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Kranti A Mapuskar (KA)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Melissa A Fath (MA)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Bryan G Allen (BG)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Douglas R Spitz (DR)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Michael S Petronek (MS)

Department of Radiation Oncology, Division of Free Radical and Radiation Biology, University of Iowa, Iowa City, IA 52242, USA.

Classifications MeSH